News >

Pembrolizumab Demonstrates Safety and Efficacy in Cervical Cancer

Jason Harris
Published: Friday, Nov 03, 2017

cervical cancer In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.

Six patients experienced immune-mediated AEs including grade 3 rash (n = 2), colitis (n = 1), and Guillain-Barre ́ syndrome (n = 1), and 1 each of grade 2 hyperthyroidism and hypothyroidism.
Frenel JS, Le Tourneau C, O’Neil, B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial [published online ahead of print November 2, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.74.5471.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication